ScreenerHero

ALKSAlkermes plc

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · alkermes.com
48.33USDMkt Cap: 8.11B $P/E: 127.18

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Irel…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8
HIK
Hikma Pharmaceuticals PLC
$4.35BUSDP/E 12.7

Key Statistics

Company
Market Cap8.11B $
Enterprise Value9.02B $
Revenue (TTM)1.67B $
Gross Profit1.28B $
Net Income (TTM)241.66M $
Revenue/Share10.05 USD
Last Price48.33 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)127.18
P/E (Forward)26.44
PEG1.96
EV/EBITDA31.67
EV/Revenue5.41
P/S4.86
P/B4.48
EPS (TTM)0.38
EPS (Forward)1.83
52W Range
47.3375% of range48.67
52W High48.67 USD
52W Low47.33 USD
Profitability
Gross Margin86.69%
Oper. Margin15.50%
EBITDA Margin17.09%
Profit Margin16.37%
ROE13.28%
ROA9.72%
Growth
Revenue Growth27.00%
Earnings Growth-99.40%
Cash Flow & Leverage
Operating CF520.75M $
CapEx (TTM)40.42M $
FCF Margin9.20%
FCF Yield1.89%
Net Debt915.99M $
Net Debt/EBITDA3.21
Balance Sheet
Debt/Equity0.04
Current Ratio2.30
Quick Ratio1.68
Book Value/Sh10.79 USD
Cash/Share3.914 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateMay 15, 2000
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)56.00 USD
Upside (mean)+15.9%
Target Range38.00 USD – 72.00 USD
$38.00+15.9% to mean$72.00
# Analysts17
Ownership
Shares Out.167.76M
Float154.64M
Insiders1.40%
Institutions108.78%
Short Interest
Short Ratio7.8d
Short % Float11.90%
Short % Out.8.59%
Shares Short14.41M
Short (prev mo.)17.46M
Technical
SMA 5050.29 (-3.9%)
SMA 20036.89 (+31.0%)
Beta0.27
S&P 52W Chg19.18%
Avg Vol (30d)859.76K
Avg Vol (10d)1.29M
Technical Indicators
RSI (14)43.6
MACD-0.3537
MACD Signal-0.1755
MACD Hist.-0.1781
BB Upper51.55 USD
BB Middle49.51 USD
BB Lower47.47 USD
BB Width8.25%
ATR (14)1.769 USD
Vol Ratio (20d)0.52x